Black Diamond Therapeutics Q2 2026 net loss $9.9M; silevertinib shows 60% ORR in NSCLC

Black Diamond Therapeutics, Inc.

Cash, equivalents, and investments $110.5M as of June 30, 2026; runway into 2H 2028.
Net loss $9.9M vs $10.6M in Q2 2025; R&D expenses $7.4M, G&A $4.7M.
Phase 2 silevertinib in frontline non-classical EGFRm NSCLC: ORR 60%, CNS ORR 86%, median PFS 15.2 months.
No patients developed de novo brain metastases; 53% remain on therapy, longest 23.5 months.
FDA feedback on pivotal path for silevertinib in frontline NSCLC expected Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.